Radiobotics Strengthens Management Team in Line With Their Commercial Strategy and Ambitions

International commercialisation is key in the strategy at Danish Radiobotics and appointing Peter Ulvskjold as new CEO will bring the award-winning health tech company to the next level.

AiThority Interview Insights : AiThority Interview with Babak Pahlavan, Founder and CEO of NinjaTech AI

Peter Ulvskjold comes from a long career of commercialisation and sales within the life science industry. He has more than +20 years of pharma and med tech experience working internationally with General Management, commercialisation, strategic execution, and globalisation in various senior management roles at Novo Nordisk, ConvaTec and latest as CEO for the Swedish biotech company Atlas Antibodies.

Peter Ulvskjold has the right combination of commercial experience, insight into the medical device industry, people management, strategy, and international outlook to accelerate Radiobotics’ ambitious journey.

“Peter’s comprehensive international experience combined with Radiobotics’ knowledgeable team generates the right mix for the company to accelerate its distribution of AI technology solutions to the market”, says Bo Heide-Ottosen, Chairman of the board.

Mads Jarner Brevadt, Co-founder and acting CEO adds:
“I am personally very impressed by Peter, and I believe that he is the perfect match for Radiobotics, taking charge of the next step of the company’s development and ambitions towards being a specialised leader in the AI radiology space. The entire team and I are looking very much forward to welcome him onboard”.

Mads Jarner Brevadt will now enter the role as COO where he in close partnership with Peter Ulvskjold and the rest of the management team will execute on Radiobotics’ commercial and international ambitions.

Read More about Interview AiThority: AiThority Interview with Gijs van de Nieuwegiessen, VP of Automation at Khoros

“I am thrilled to join Radiobotics as its new CEO. The company has a disruptive radiology AI technology that will and is already improving patient outcomes. The organisation has over the past years built an industry leading platform, and now it is time for global commercialisation and bringing this revolutionary technology to the medical field internationally. I am honoured to help build that and lead our dedicated team towards even greater success”, says new CEO, Peter Ulvskjold.

Radiobotics has an overall ambition to contribute to the development of the healthcare industry as a whole and the field of radiology in particular. This means building AI-driven products to support analysis and reading of medical X-rays of bone and joints: RBfractureTM for detecting fractures in trauma X-rays of the entire skeleton, RBkneeTM for analysing knee osteoarthritis and RBhipTM for analysing hip dysplasia and impingement.

Radiobotics is a multiple award-winning health tech company founded in Denmark in 2017. The company has developed an innovative AI technology specialized in X-ray analysis with a focus on creating AI-driven software products for musculoskeletal radiology. This empowers clinicians to boost their performance when reading medical X-ray images, increasing diagnostic accuracy and efficiency – to benefit both patients and hospitals. Radiobotics’ certified algorithms are based on deep clinical understanding and the technology is designed in close collaboration with frontline clinicians.

 Latest AiThority Interview Insights : AiThority Interview with Keri Olson, VP at IBM IT Automation

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Radiobotics Strengthens Management Team in Line With Their Commercial Strategy and Ambitions appeared first on AiThority.

antibodies
medical
biotech
pharma
healthcare
diagnostic
bone
radiology
health
device
ai
software